Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Shibata, K.
Right arrow Articles by Mori, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shibata, K.
Right arrow Articles by Mori, T.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Japanese Journal of Clinical Oncology 21:13-21 (1991)
© 1991 Foundation for Promotion of Cancer Research


research-article

Production of Three Monoclonal Antibodies Specifically Reactive Respectively with the Ductal, Acinar and Islet Cells of the Human Pancreas

Kunitaka Shibata*, Tetsuro Kobayashi, Nariaki Matsuura, Takashi Shimano and Takesada Mori

Second Department of Surgery, Osaka University Medical School 1-50 Fukushima 1-chome, Fukushiama-ku Osaka 553

*For reprints and all correspondence

Received April 25, 1990; accepted October 19, 1990

Three monoclonal antibodies, designated FP-1, FP-2 and FP-3, were obtained by immunizing a BALB/c mouse with dispersed human fetal pancreatic cells and using hybridoma technology. FP-1, FP-2 and FP-3 reacted specifically, respectively, with the ductal epithelial, acinar and islet cells, of the fetal pancreas as well as with adult human pancreatic tissue, suggesting a use in the discrimination of pancreatic cell types. Upon screening various tumor tissues, FP-1 was found to react with adenocarcinomas of the pancreas (16/23), stomach (7/8), colon (4/6) and gall bladder (2/2) as well as with the three malignant cell lines, PANC-1 (pancreas), HT-29 (colon) and LoVo (colon). In contrast to FP-1, FP-2 and FP-3 reacted with only 5% (2/39) and 0% (0/39), respectively, of these adenocarcinomas. Although FP-3 did not react with any of these adenocarcinomas, it did react with various APUDoma cells such as islet cell tumors of the pancreas (3/5), pheochromocytomas (2/2), medullary thyroid carcinomas (2/3) and gastrointestinal carcinoids (1/3). FP-3 thus appears to be the first monoclonal antibody with extremely high endocrine cell specificity.

Key Words: Monoclonal antibody • Fetal pancreas • Pancreatic cancer • APUDoma cell • Endocrine cell


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.